Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

Identifying prognostic indicators for risk stratification in metastatic renal cell carcinoma (mRCC) is crucial for optimizing treatment strategies and follow-up plans. This study aims to investigate the prognostic role of the glucose-to-lymphocyte ratio (GLR) in patients with mRCC receiving tyrosine...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & translational oncology 2025-01
Main Authors: Bolek, Hatice, Kuzu, Omer Faruk, Sertesen Camoz, Elif, Sim, Saadet, Sekmek, Serhat, Karakas, Hilal, Isık, Selver, Günaltılı, Murat, Akkus, Aysun Fatma, Tural, Deniz, Arslan, Cagatay, Goksu, Sema Sezin, Sever, Ozlem Nuray, Karadurmus, Nuri, Karacin, Cengiz, Sendur, Mehmet Ali Nahit, Yekedüz, Emre, Urun, Yuksel
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c184t-7df255f0c9a389c3cb7fdf578d65171858838a692163685a3c3a2ef8fd90af043
container_end_page
container_issue
container_start_page
container_title Clinical & translational oncology
container_volume
creator Bolek, Hatice
Kuzu, Omer Faruk
Sertesen Camoz, Elif
Sim, Saadet
Sekmek, Serhat
Karakas, Hilal
Isık, Selver
Günaltılı, Murat
Akkus, Aysun Fatma
Tural, Deniz
Arslan, Cagatay
Goksu, Sema Sezin
Sever, Ozlem Nuray
Karadurmus, Nuri
Karacin, Cengiz
Sendur, Mehmet Ali Nahit
Yekedüz, Emre
Urun, Yuksel
description Identifying prognostic indicators for risk stratification in metastatic renal cell carcinoma (mRCC) is crucial for optimizing treatment strategies and follow-up plans. This study aims to investigate the prognostic role of the glucose-to-lymphocyte ratio (GLR) in patients with mRCC receiving tyrosine kinase inhibitors (TKIs) as first-line therapy. A retrospective cohort study was conducted using data from the Turkish Oncology Group Kidney Cancer Consortium Database. GLR was calculated by dividing the fasting glucose (mmol/L) by the lymphocyte count (×10 /L). We categorized patients into two categories based on their median GLR level. The analysis included a total of 598 patients. We found that progression-free survival (PFS) was significantly longer in the GLR-low group, with a median PFS of 15.05 months (95% CI 12.7-17.4) compared to 7.79 months (95% CI 6.6-9.0) in the GLR-high group (p 
doi_str_mv 10.1007/s12094-024-03813-w
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3155720750</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3155720750</sourcerecordid><originalsourceid>FETCH-LOGICAL-c184t-7df255f0c9a389c3cb7fdf578d65171858838a692163685a3c3a2ef8fd90af043</originalsourceid><addsrcrecordid>eNpNUcFu1DAUjBCIlsIPcEDvWA4BO14nDjcUlYJaqZflHHmd542pYwfbYZVv5ifw7hbE4fmN5JnR00xRvKXkAyWk-RhpRdpNSao8TFBWHp4Vl7Ru25IRzp__hy-KVzH-IBnVlL4sLlgraNWy5rL4ffNL2kUm4_aQRoQ5-L3zMRkFwVsEr2FvF-UjlsmXdp3m0as1IYSs8WAczBmgSxEOJo0wYZIxyZMenbSg0OZHBmWcnySkgDLhcCanNfhoHMKjcTJidhvNziQf4tFYmxAT2Pz_CSTEtAwr7NbTldslPJo4woNT3vr9CrfBLzPcmcHhCp10CgN03kUfklkmuN7edd3718ULLW3EN0_7qvj-5WbbfS3vH26_dZ_vS0XFJpXNoCvONVGtZKJVTO0aPWjeiKHmtKGCC8GErNuK1qwWXDLFZIVa6KElUpMNuyquz745zJ8LxtRPJh5zkA79EntGOW8q0nCSqdWZqnISMaDu52AmGdaekv5Ycn8uuc8l96eS-0MWvXvyX3YTDv8kf1tlfwBnU6jb</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3155720750</pqid></control><display><type>article</type><title>Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC)</title><source>Springer Nature</source><creator>Bolek, Hatice ; Kuzu, Omer Faruk ; Sertesen Camoz, Elif ; Sim, Saadet ; Sekmek, Serhat ; Karakas, Hilal ; Isık, Selver ; Günaltılı, Murat ; Akkus, Aysun Fatma ; Tural, Deniz ; Arslan, Cagatay ; Goksu, Sema Sezin ; Sever, Ozlem Nuray ; Karadurmus, Nuri ; Karacin, Cengiz ; Sendur, Mehmet Ali Nahit ; Yekedüz, Emre ; Urun, Yuksel</creator><creatorcontrib>Bolek, Hatice ; Kuzu, Omer Faruk ; Sertesen Camoz, Elif ; Sim, Saadet ; Sekmek, Serhat ; Karakas, Hilal ; Isık, Selver ; Günaltılı, Murat ; Akkus, Aysun Fatma ; Tural, Deniz ; Arslan, Cagatay ; Goksu, Sema Sezin ; Sever, Ozlem Nuray ; Karadurmus, Nuri ; Karacin, Cengiz ; Sendur, Mehmet Ali Nahit ; Yekedüz, Emre ; Urun, Yuksel</creatorcontrib><description>Identifying prognostic indicators for risk stratification in metastatic renal cell carcinoma (mRCC) is crucial for optimizing treatment strategies and follow-up plans. This study aims to investigate the prognostic role of the glucose-to-lymphocyte ratio (GLR) in patients with mRCC receiving tyrosine kinase inhibitors (TKIs) as first-line therapy. A retrospective cohort study was conducted using data from the Turkish Oncology Group Kidney Cancer Consortium Database. GLR was calculated by dividing the fasting glucose (mmol/L) by the lymphocyte count (×10 /L). We categorized patients into two categories based on their median GLR level. The analysis included a total of 598 patients. We found that progression-free survival (PFS) was significantly longer in the GLR-low group, with a median PFS of 15.05 months (95% CI 12.7-17.4) compared to 7.79 months (95% CI 6.6-9.0) in the GLR-high group (p &lt; 0.001). Multivariate analysis identified GLR as an independent risk factor for poor PFS (HR 1.39, 95% CI 1.12-1.72; p = 0.003). Overall survival (OS) was also significantly longer in the GLR-low group, with a median OS of 38.47 months (95% CI, 30.9-46.0) compared to 24.15 months (95% CI 18.0-30.2) in the GLR-high group (p = 0.001). GLR was an independent predictor for OS in multivariate analysis (HR 1.45, 95% CI 1.12-1.86; p = 0.004). The GLR can be a valuable prognostic marker for glucose metabolism and systemic inflammatory status in this patient population. Our research highlights the potential prognostic value of GLR in patients with mRCC receiving TKIs, indicating its potential as a useful tool for clinical decision-making.</description><identifier>ISSN: 1699-3055</identifier><identifier>EISSN: 1699-3055</identifier><identifier>DOI: 10.1007/s12094-024-03813-w</identifier><identifier>PMID: 39812937</identifier><language>eng</language><publisher>Italy</publisher><ispartof>Clinical &amp; translational oncology, 2025-01</ispartof><rights>2025. The Author(s).</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c184t-7df255f0c9a389c3cb7fdf578d65171858838a692163685a3c3a2ef8fd90af043</cites><orcidid>0000-0002-9152-9887</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39812937$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bolek, Hatice</creatorcontrib><creatorcontrib>Kuzu, Omer Faruk</creatorcontrib><creatorcontrib>Sertesen Camoz, Elif</creatorcontrib><creatorcontrib>Sim, Saadet</creatorcontrib><creatorcontrib>Sekmek, Serhat</creatorcontrib><creatorcontrib>Karakas, Hilal</creatorcontrib><creatorcontrib>Isık, Selver</creatorcontrib><creatorcontrib>Günaltılı, Murat</creatorcontrib><creatorcontrib>Akkus, Aysun Fatma</creatorcontrib><creatorcontrib>Tural, Deniz</creatorcontrib><creatorcontrib>Arslan, Cagatay</creatorcontrib><creatorcontrib>Goksu, Sema Sezin</creatorcontrib><creatorcontrib>Sever, Ozlem Nuray</creatorcontrib><creatorcontrib>Karadurmus, Nuri</creatorcontrib><creatorcontrib>Karacin, Cengiz</creatorcontrib><creatorcontrib>Sendur, Mehmet Ali Nahit</creatorcontrib><creatorcontrib>Yekedüz, Emre</creatorcontrib><creatorcontrib>Urun, Yuksel</creatorcontrib><title>Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC)</title><title>Clinical &amp; translational oncology</title><addtitle>Clin Transl Oncol</addtitle><description>Identifying prognostic indicators for risk stratification in metastatic renal cell carcinoma (mRCC) is crucial for optimizing treatment strategies and follow-up plans. This study aims to investigate the prognostic role of the glucose-to-lymphocyte ratio (GLR) in patients with mRCC receiving tyrosine kinase inhibitors (TKIs) as first-line therapy. A retrospective cohort study was conducted using data from the Turkish Oncology Group Kidney Cancer Consortium Database. GLR was calculated by dividing the fasting glucose (mmol/L) by the lymphocyte count (×10 /L). We categorized patients into two categories based on their median GLR level. The analysis included a total of 598 patients. We found that progression-free survival (PFS) was significantly longer in the GLR-low group, with a median PFS of 15.05 months (95% CI 12.7-17.4) compared to 7.79 months (95% CI 6.6-9.0) in the GLR-high group (p &lt; 0.001). Multivariate analysis identified GLR as an independent risk factor for poor PFS (HR 1.39, 95% CI 1.12-1.72; p = 0.003). Overall survival (OS) was also significantly longer in the GLR-low group, with a median OS of 38.47 months (95% CI, 30.9-46.0) compared to 24.15 months (95% CI 18.0-30.2) in the GLR-high group (p = 0.001). GLR was an independent predictor for OS in multivariate analysis (HR 1.45, 95% CI 1.12-1.86; p = 0.004). The GLR can be a valuable prognostic marker for glucose metabolism and systemic inflammatory status in this patient population. Our research highlights the potential prognostic value of GLR in patients with mRCC receiving TKIs, indicating its potential as a useful tool for clinical decision-making.</description><issn>1699-3055</issn><issn>1699-3055</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><recordid>eNpNUcFu1DAUjBCIlsIPcEDvWA4BO14nDjcUlYJaqZflHHmd542pYwfbYZVv5ifw7hbE4fmN5JnR00xRvKXkAyWk-RhpRdpNSao8TFBWHp4Vl7Ru25IRzp__hy-KVzH-IBnVlL4sLlgraNWy5rL4ffNL2kUm4_aQRoQ5-L3zMRkFwVsEr2FvF-UjlsmXdp3m0as1IYSs8WAczBmgSxEOJo0wYZIxyZMenbSg0OZHBmWcnySkgDLhcCanNfhoHMKjcTJidhvNziQf4tFYmxAT2Pz_CSTEtAwr7NbTldslPJo4woNT3vr9CrfBLzPcmcHhCp10CgN03kUfklkmuN7edd3718ULLW3EN0_7qvj-5WbbfS3vH26_dZ_vS0XFJpXNoCvONVGtZKJVTO0aPWjeiKHmtKGCC8GErNuK1qwWXDLFZIVa6KElUpMNuyquz745zJ8LxtRPJh5zkA79EntGOW8q0nCSqdWZqnISMaDu52AmGdaekv5Ycn8uuc8l96eS-0MWvXvyX3YTDv8kf1tlfwBnU6jb</recordid><startdate>20250115</startdate><enddate>20250115</enddate><creator>Bolek, Hatice</creator><creator>Kuzu, Omer Faruk</creator><creator>Sertesen Camoz, Elif</creator><creator>Sim, Saadet</creator><creator>Sekmek, Serhat</creator><creator>Karakas, Hilal</creator><creator>Isık, Selver</creator><creator>Günaltılı, Murat</creator><creator>Akkus, Aysun Fatma</creator><creator>Tural, Deniz</creator><creator>Arslan, Cagatay</creator><creator>Goksu, Sema Sezin</creator><creator>Sever, Ozlem Nuray</creator><creator>Karadurmus, Nuri</creator><creator>Karacin, Cengiz</creator><creator>Sendur, Mehmet Ali Nahit</creator><creator>Yekedüz, Emre</creator><creator>Urun, Yuksel</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9152-9887</orcidid></search><sort><creationdate>20250115</creationdate><title>Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC)</title><author>Bolek, Hatice ; Kuzu, Omer Faruk ; Sertesen Camoz, Elif ; Sim, Saadet ; Sekmek, Serhat ; Karakas, Hilal ; Isık, Selver ; Günaltılı, Murat ; Akkus, Aysun Fatma ; Tural, Deniz ; Arslan, Cagatay ; Goksu, Sema Sezin ; Sever, Ozlem Nuray ; Karadurmus, Nuri ; Karacin, Cengiz ; Sendur, Mehmet Ali Nahit ; Yekedüz, Emre ; Urun, Yuksel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c184t-7df255f0c9a389c3cb7fdf578d65171858838a692163685a3c3a2ef8fd90af043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bolek, Hatice</creatorcontrib><creatorcontrib>Kuzu, Omer Faruk</creatorcontrib><creatorcontrib>Sertesen Camoz, Elif</creatorcontrib><creatorcontrib>Sim, Saadet</creatorcontrib><creatorcontrib>Sekmek, Serhat</creatorcontrib><creatorcontrib>Karakas, Hilal</creatorcontrib><creatorcontrib>Isık, Selver</creatorcontrib><creatorcontrib>Günaltılı, Murat</creatorcontrib><creatorcontrib>Akkus, Aysun Fatma</creatorcontrib><creatorcontrib>Tural, Deniz</creatorcontrib><creatorcontrib>Arslan, Cagatay</creatorcontrib><creatorcontrib>Goksu, Sema Sezin</creatorcontrib><creatorcontrib>Sever, Ozlem Nuray</creatorcontrib><creatorcontrib>Karadurmus, Nuri</creatorcontrib><creatorcontrib>Karacin, Cengiz</creatorcontrib><creatorcontrib>Sendur, Mehmet Ali Nahit</creatorcontrib><creatorcontrib>Yekedüz, Emre</creatorcontrib><creatorcontrib>Urun, Yuksel</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical &amp; translational oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bolek, Hatice</au><au>Kuzu, Omer Faruk</au><au>Sertesen Camoz, Elif</au><au>Sim, Saadet</au><au>Sekmek, Serhat</au><au>Karakas, Hilal</au><au>Isık, Selver</au><au>Günaltılı, Murat</au><au>Akkus, Aysun Fatma</au><au>Tural, Deniz</au><au>Arslan, Cagatay</au><au>Goksu, Sema Sezin</au><au>Sever, Ozlem Nuray</au><au>Karadurmus, Nuri</au><au>Karacin, Cengiz</au><au>Sendur, Mehmet Ali Nahit</au><au>Yekedüz, Emre</au><au>Urun, Yuksel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC)</atitle><jtitle>Clinical &amp; translational oncology</jtitle><addtitle>Clin Transl Oncol</addtitle><date>2025-01-15</date><risdate>2025</risdate><issn>1699-3055</issn><eissn>1699-3055</eissn><abstract>Identifying prognostic indicators for risk stratification in metastatic renal cell carcinoma (mRCC) is crucial for optimizing treatment strategies and follow-up plans. This study aims to investigate the prognostic role of the glucose-to-lymphocyte ratio (GLR) in patients with mRCC receiving tyrosine kinase inhibitors (TKIs) as first-line therapy. A retrospective cohort study was conducted using data from the Turkish Oncology Group Kidney Cancer Consortium Database. GLR was calculated by dividing the fasting glucose (mmol/L) by the lymphocyte count (×10 /L). We categorized patients into two categories based on their median GLR level. The analysis included a total of 598 patients. We found that progression-free survival (PFS) was significantly longer in the GLR-low group, with a median PFS of 15.05 months (95% CI 12.7-17.4) compared to 7.79 months (95% CI 6.6-9.0) in the GLR-high group (p &lt; 0.001). Multivariate analysis identified GLR as an independent risk factor for poor PFS (HR 1.39, 95% CI 1.12-1.72; p = 0.003). Overall survival (OS) was also significantly longer in the GLR-low group, with a median OS of 38.47 months (95% CI, 30.9-46.0) compared to 24.15 months (95% CI 18.0-30.2) in the GLR-high group (p = 0.001). GLR was an independent predictor for OS in multivariate analysis (HR 1.45, 95% CI 1.12-1.86; p = 0.004). The GLR can be a valuable prognostic marker for glucose metabolism and systemic inflammatory status in this patient population. Our research highlights the potential prognostic value of GLR in patients with mRCC receiving TKIs, indicating its potential as a useful tool for clinical decision-making.</abstract><cop>Italy</cop><pmid>39812937</pmid><doi>10.1007/s12094-024-03813-w</doi><orcidid>https://orcid.org/0000-0002-9152-9887</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1699-3055
ispartof Clinical & translational oncology, 2025-01
issn 1699-3055
1699-3055
language eng
recordid cdi_proquest_miscellaneous_3155720750
source Springer Nature
title Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC)
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T21%3A22%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluating%20the%20prognostic%20role%20of%20glucose-to-lymphocyte%20ratio%20in%20patients%20with%20metastatic%20renal%20cell%20carcinoma%20treated%20with%20tyrosine%20kinase%20inhibitors%20in%20first%20line:%20a%20study%20by%20the%20Turkish%20Oncology%20Group%20Kidney%20Cancer%20Consortium%20(TKCC)&rft.jtitle=Clinical%20&%20translational%20oncology&rft.au=Bolek,%20Hatice&rft.date=2025-01-15&rft.issn=1699-3055&rft.eissn=1699-3055&rft_id=info:doi/10.1007/s12094-024-03813-w&rft_dat=%3Cproquest_cross%3E3155720750%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c184t-7df255f0c9a389c3cb7fdf578d65171858838a692163685a3c3a2ef8fd90af043%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3155720750&rft_id=info:pmid/39812937&rfr_iscdi=true